General Partner
Phone: +41 61 270 35 63
Prior to joining MPM in 2002, he was at Roche, where he served for nearly 20 years in several senior management positions in the Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D. He organized and served on the Global Board of R&D Directors and the Pharma Portfolio Board. Most recently he was VP and CSO of Genetics and Integrated Medicine and a member of the Roche Genetics Executive Committee.
Dr. Hosang received his M.S. and Ph.D. degrees in Biochemistry from the ETH in Zurich, and pursued his postgraduate training at Stanford University Medical School and at the University of Washington in Seattle. He served as a member of the Board and as the Treasurer of the Swiss Foundation for Stipends in Biology and Medicine for many years.
General Partner
Phone: +41 61 270 35 67
Until 2003 he worked as Chief Financial Officer at NMT New Medical Technologies focusing on private equity investments in biopharmaceutical and biotechnological companies. He was financial advisor in several private biotechnology investments of NMT and responsible for financial aspects of the portfolio companies of NMT.
Before joining NMT, he worked from 1992-2001 as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States gaining vast experience in early stage and start-up companies in the life science sector as well as large multinational organizations.
Mr. Möller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.
Partner
Phone: +41 61 270 35 61
Prior to Novartis, he was Senior Financial Analyst responsible for the European Biotech and Pharma sector at Zürcher Kantonalbank. In addition, he served as advisor to the healthcare fund Pharma Vision. Before that, he worked as strategic planning manager at Jomed AG (now Abbott Vascular).
Mr. Burgermeister headed the business development at Apeiron Biologics (Vienna, Austria) where he was instrumental in several licensing deals. He also served as chairman of a dermatology startup and is board member of the business angel club BioBAC.
Mr. Burgermeister holds a Master degree in Molecular Biology from the University of Basel (Biozentrum), a Master degree in Business Administration from the University of St. Gallen (HSG) and a degree as Chartered Financial Analyst (CFA).
CFO / Partner
Phone: +41 61 270 35 51
In addition, Mr. Fäs is a certified auditor.
Until 2002, he worked as an Assistant at UBS Asset Management Zurich, making Investment analysis of medtech companies.
For more than four years he was Audit Manager at Ernst & Young AG, Basel, where he audited and advised medium-sized and international industry companies, particularly Biotech and Life Science companies.
Before joining BioMedPartners, he worked as a Manager at Helbling Corporate Finance, Zurich, focusing on transaction services, financial due diligence and merger & acquisitions in the industry sector including Healthcare and Medical Technology.
Partner
Phone: +41 61 270 35 53
capital and academia.
Previously, Dr. Fischer has been working for WestLB in the healthcare and chemicals sector where he was heading the equity capital markets team realizing large primary market transactions and the strategic analysis working on debt, M&A, and equity transactions.
He started his career with Deutsche Venture Capital, an affiliate of Deutsche Bank, investing into bio- and medical technology companies. He then consulted large cap pharmaceutical companies with McKinsey&Company on sales and marketing strategies before he went to Sanofi Aventis being responsible for Sales Force and Marketing Excellence.
He has a biochemistry and economics background and holds a PhD in infection biology (MPI Infection Biology and Colorado State University).
Venture Partner
Phone: +41 61 270 35 62
Dr. Piëch holds a PhD in Neuroscience from the Rockefeller University in New York, a Master degree in Cognitive and Neural Systems from Boston University and a Master Degree in Mechanical and Process Engineering from the Federal Institute of Technology in Zurich (ETH).
Partner
Phone: +41 61 270 35 52
Dr. Wallnöfer had also a key role in the integration of the Roche and Genentech Development organizations and led subsequently Early Development and Portfolio Management at Roche. He will strengthen BioMed expertise in Pharma from discovery to regulatory filing submissions.
Dr. Wallnöfer has a PhD in pharmacology from the University of Basel and trained as a fellow in Clinical Pharmacology at the University of Leiden, the Netherlands. He holds a Master of Technology Enterprise and an Executive MBA from IMD Lausanne.
Credit Advisor |
Office |
||
 |
Josef Bissig
Venture Partner
E-mail:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone:
+41 61 270 35 52
|
 |
Fiona Lauscher
Office Manager
E-mail:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone:
+41 61 270 35 35
|